# Case Report: An incidentally discovered HPV-associated endocervical adenocarcinoma presenting as pseudomyxoma peritonei

**Authors:** Lijun Chen, Lin Sun

PMC · DOI: 10.3389/fonc.2025.1630879 · 2026-01-14

## TL;DR

A woman with an undetected HPV-related cervical cancer presented with symptoms resembling a rare abdominal condition, highlighting the importance of accurate diagnosis using advanced testing.

## Contribution

This case highlights the importance of immunohistochemical profiling in diagnosing metastatic cervical adenocarcinoma mimicking pseudomyxoma peritonei.

## Key findings

- HPV-associated endocervical adenocarcinoma can present as pseudomyxoma peritonei-like ascites without cervical abnormalities.
- Immunohistochemistry (p16, ER, PR, Ki-67) is critical for distinguishing metastatic from primary ovarian tumors.
- Transtubal dissemination is a possible metastatic pathway for cervical adenocarcinoma.

## Abstract

This case report describes a 48-year-old woman with occult HPV-associated endocervical adenocarcinoma (Silva pattern B) presenting as bilateral ovarian metastases and pseudomyxoma peritonei–like gelatinous ascites, despite normal cervical morphology and resolved HPV type 45 infection. Initial misdiagnosis as primary ovarian mucinous carcinoma was revised based on histopathology and immunohistochemistry (diffuse p16 positivity, ER-negative and PR-negative, Ki-67 index of 95%), confirming metastatic endocervical adenocarcinoma. The absence of appendiceal lesions excluded true PMP, attributing ascites to tumor mucin secretion. This case highlights the diagnostic challenges of occult cervical adenocarcinoma mimicking PMP and underscores the critical role of immunohistochemical profiling (p16, PAX8, WT1) to differentiate metastatic from primary ovarian tumors. The study emphasizes a multidisciplinary approach for accurate classification of mucinous neoplasms and raises awareness of rare metastatic pathways, such as transtubal dissemination, in HPV-associated cervical adenocarcinoma.

## Linked entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], EREG (epiregulin) [NCBI Gene 2069], PGR (progesterone receptor) [NCBI Gene 5241], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], PAX8 (paired box 8) [NCBI Gene 7849], WT1 (WT1 transcription factor) [NCBI Gene 7490]
- **Diseases:** pseudomyxoma peritonei (MONDO:0017048)

## Full-text entities

- **Genes:** mucin [NCBI Gene 100508689], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}, WT1 (WT1 transcription factor) [NCBI Gene 7490] {aka AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** mucinous neoplasms (MESH:D018297), ovarian metastases (MESH:D010049), pseudomyxoma peritonei (MESH:D011553), ovarian mucinous carcinoma (MESH:D010051), tumor (MESH:D009369), primary (MESH:D010538), pattern B (MESH:D006509), cervical adenocarcinoma (MESH:D000230), ascites (MESH:D001201), appendiceal lesions (MESH:D001063)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12828276/full.md

---
Source: https://tomesphere.com/paper/PMC12828276